Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
46/100
Neocortical tracer retention was highly comparable using both SUVR and distribution volume ratio-1 values obtained from dynamic scans.
-
The outer plexiform layer line had one of the lowest mean error ratios (2%), while RNFL had the highest (23%).
-
It might constitute a simple, cost-effective and reproducible in vivo proxy of AD suitable to be adopted worldwide not only in daily clinical practice but also in future experimental trials, to avoid the enrolment of misdiagnosed AD patients.
-
Forty-four consecutive patients with clinical evidence of dementia, were retrospectively evaluated.
-
Brain amyloid-β (Aβ) deposition is a hallmark to define Alzheimer's disease (AD).
-
To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer's disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24).
-
Cerebrospinal fluid (CSF) biomarkers have been extensively investigated in idiopathic normal pressure hydrocephalus (iNPH) with the aim of a better differential diagnosis, but the pathophysiological mechanisms underlying CSF biomarker changes and the relationship between biomarker levels and clinical variables are still a matter of debate.
-
46/100
CSF-sLR11 concentrations were higher in patients with AD than controls (adjusted for sLR11 using phospholipid).
-
Cerebrospinal fluid (CSF) neurofilament light (NFL) is a protein biomarker of axonal injury.
-
Among the 12 patients with PPA syndrome, 8 (66.7%) were considered as amyloid positive.
-
46/100
The ratio CSF p-tau/t-tau was significantly higher in the NC group than that in the AD or OD groups (P<0.0005 for each group).
-
Cognitive reserve (CR) is defined as the ability to maintain functionality despite accumulating pathology.
-
17 out of 33 patients were scored as FBB-PET positive.
-
The 88 patients with AD included 15 with microbleeds only in cortical/subcortical regions (cortical microbleeds) that could be CAA-related, 16 with microbleeds only in deep locations (deep microbleeds), 3 with microbleeds in both cortical and deep locations (mixed microbleeds), and 54 without microbleeds.
-
46/100
Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, thalamus, and striatum.
-
Amyloid β (Aβ) peptides are important components of plaques in patients with Alzheimer's disease (AD).
-
c GMP , and not c AMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls.
-
Specific biomarkers in a readily accessible biological fluid, such as blood, could aid in the identification, characterization, validation, and routine monitoring of Alzheimer's disease (AD) progression.
-
To improve clinical, neuropsychological and behavioural characterisation of the cerebrospinal fluid (CSF) biomarkers beta-amyloid((1-42)) protein (Abeta42), protein tau (tau) and tau phosphorylated at threonine 181 (P-tau181) across diagnostic dementia categories, a prospective study was set up.
-
Validated plasma phosphorylated tau 217 (p-tau217) assays identify Alzheimer disease pathology with high accuracy.
-
No significant differences in p-tau217, GFAP and NfL level were observed between groups (pFDR > 0.08).
-
Dementia with Lewy bodies (DLB), a synucleinopathy, is the second most common form of dementia after Alzheimer's disease (AD).
-
The recent advent of anti-amyloid-β monoclonal antibodies has introduced new demands for MRI-based screening of amyloid-related imaging abnormalities, particularly the hemorrhage subtype (ARIA-H).
-
Phosphorylated-tau 217 (pTau217) is currently the most promising blood-based biomarker for accurately detecting Alzheimer's disease (AD) pathology.
-
Alzheimer's disease (AD) presents a critical global challenge, accounting for over 60 % of the 57 million current dementia cases worldwide, with prevalence projected to exceed 100 million by 2050.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia
- HDL from an Alzheimer's disease perspective
- Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia
- MRI quantification of non-Gaussian water diffusion by kurtosis analysis
- Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
- Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau
- Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
- Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks
- Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
- The Eye as a Diagnostic Tool for Alzheimer's Disease